- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | Alpha Teknova stellt Wachstumsplan vor: EBITDA-Profitabilität bis 2027 angestrebt | 1 | Investing.com Deutsch | ||
| 02.03. | Alpha Teknova, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.02. | Alpha Teknova, Inc. Q4 Loss Decreases | - | RTTNews | ||
| 27.02. | Teknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilities | 2 | Seeking Alpha | ||
| 27.02. | Teknova Q4 2025 slides: gross margins surge to 33% on efficiency gains | 1 | Investing.com | ||
| 26.02. | Alpha Teknova GAAP EPS of $0.09 beats by $0.18, revenue of $10M beats by $0.39M | 1 | Seeking Alpha | ||
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 26.02. | Alpha Teknova, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | 2 | GlobeNewswire (USA) | ||
| 07.11.25 | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Teknova reiterates $39M-$42M 2025 revenue target while eyeing 20%-25% long-term growth amid operational advances | 2 | Seeking Alpha | ||
| 06.11.25 | Alpha Teknova GAAP EPS of -$0.08 beats by $0.01, revenue of $10.5M beats by $0.27M | 1 | Seeking Alpha | ||
| 06.11.25 | Alpha Teknova, Inc.: Teknova Reports Third Quarter 2025 Financial Results | 149 | GlobeNewswire (Europe) | Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million... ► Artikel lesen | |
| 28.10.25 | Alpha Teknova, Inc.: Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025 | 4 | GlobeNewswire (USA) | ||
| 20.10.25 | Alpha Teknova (TKNO) Surged Following Accelerated Demand | 2 | Insider Monkey |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,915 | +1,60 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,21 | +8,35 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| EVOTEC | 5,390 | +14,68 % | Evotec: Aktivistischer Investor macht Druck - die Hintergründe | Die Aktie des Hamburger Wirkstoffforschers Evotec hat den Anlegern in den zurückliegenden Jahren nur wenig Freude bereitet. Der Titel rutschte sogar vor kurzem auf ein neues Mehrjahrestief ab. Das ruft... ► Artikel lesen | |
| BIONTECH | 83,55 | +1,58 % | Biotech-Werte im Check: Warum Bioxyne, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| MODERNA | 44,855 | +4,07 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| TYRA BIOSCIENCES | 35,240 | -1,04 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| ERASCA | 17,830 | +9,32 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| TANGO THERAPEUTICS | 24,070 | +11,75 % | Leerink raises Tango Therapeutics stock price target on PDAC data | ||
| CG ONCOLOGY | 67,26 | -0,61 % | CG Oncology, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 36,480 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,490 | +1,16 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| IMMUNOME | 22,890 | +1,24 % | Immunome: Q4 Earnings Insights | ||
| SANA BIOTECHNOLOGY | 3,470 | +8,27 % | Morning Market Movers: Avanos Medical, Sana Biotechnology, Credo Technology Group, Bloom Energy See Big Swings | BEIJING (dpa-AFX) - At 7:30 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,280 | -25,25 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| MAZE THERAPEUTICS | 27,680 | +0,95 % | Zifo Technologies: Zifo and Maze Therapeutics Partner to Power Precision Medicine | SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc have... ► Artikel lesen |
Das Unternehmen ALPHA TEKNOVA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.